Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.44 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15816035 | 1.00 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL15815482 | 0.90 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL15815483 | 0.90 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL16293423 | 0.90 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL16293424 | 0.90 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL15817423 | 0.89 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL15816272 | 0.89 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL15816273 | 0.89 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL15817426 | 0.89 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL15816856 | 0.88 | PIK3CB (0.52) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935246-B1 | ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC. | 2016-01-21 | — | — | US | disclosed |
| US-9029384-B2 | Phosphatidylinositol 3-kinase inhibitors | Gilead Calistoga, LLC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | PIK3CD 5/4885PIK3CG 10/4885PIK3CA 2/4885 |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | PIK3CD 5/4885PIK3CG 10/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.